By Michael Erman (Reuters) -Merck & Co on Thursday reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily …
By Ludwig Burger FRANKFURT (Reuters) -Germany’s Merck KGaA on Thursday warned of a steeper earnings decline on a slump in demand for materials used to …
(Reuters) – Merck & Co expects a research-and-development charge of about $10.3 billion, or $4 per share, this year as the drugmaker accounts its deal …
SHANGHAI (Reuters) – Pfizer and Merck have slightly lowered the prices of their respective Paxlovid and molnupiravir COVID-19 treatments in China, local media reported on …
(Reuters) – Mersana Therapeutics Inc said on Thursday it had signed a deal for developing cancer drugs with Germany’s Merck KGaA that has the potential …
FRANKFURT (Reuters) – Germany’s Merck KGaA on Monday said it aims to double the productivity of its research and development into oncology, neurology and immunology …
By Michael Erman (Reuters) – Drugmaker Merck & Co avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda …
(Reuters) -Finnish drug maker Orion on Wednesday raised its full year outlook after it signed a collaboration agreement with Merck aimed at developing a prostate …
(Reuters) – Drugmaker Merck & Co is considering buying cancer-focused biotech company Seagen Inc, the Wall Street Journal reported on Friday, citing people familiar with …
TOKYO – The Japanese unit of Merck & Co Inc said on Monday it would accelerate imports of its oral COVID-19 treatment to help with …
Merck announced Friday that updated data on its experimental COVID-19 pill show the drug is less effective than previously reported, and will now move to …